Molecular Analysis for Therapy Choice (MATCH) - MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification

Protocol: 
AAAP9159
Phase: 
I

Molecular Analysis for Therapy Choice (MATCH) - MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification

To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas.

Are you Eligible? (Inclusion Criteria)

Patients must be >= 18 years of age.
Patients with advanced refractory cancers/lymphomas

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States